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Abstract
miR-124-1 is a tumour suppressor microRNA (miR). Epigenetic deregulation of miRs is implicated in carcinogenesis. Promoter
DNA methylation and histone modification of miR-124-1 was studied in 5 normal marrow controls, 4 lymphoma, 8 multiple
myeloma (MM) cell lines, 230 diagnostic primary samples of acute myeloid leukaemia (AML), acute lymphoblastic leukaemia
(ALL), chronic myeloid leukaemia (CML), chronic lymphocytic leukaemia (CLL), MM, and non-Hodgkin’s lymphoma (NHL),
and 53 MM samples at stable disease or relapse. Promoter of miR-124-1 was unmethylated in normal controls but
homozygously methylated in 4 of 4 lymphoma and 4 of 8 myeloma cell lines. Treatment of 5-Aza-29-deoxycytidine led to
miR-124-1 demethylation and re-expression of mature miR-124, which also associated with emergence of euchromatic
trimethyl H3K4 and consequent downregulation of CDK6 in myeloma cells harboring homozygous miR-124-1 methylation.
In primary samples at diagnosis, miR-124-1 methylation was absent in CML but detected in 2% each of MM at diagnosis and
relapse/progression, 5% ALL, 15% AML, 14% CLL and 58.1% of NHL (p,0.001). Amongst lymphoid malignancies, miR-124-1
was preferentially methylated in NHL than MM, CLL or ALL. In primary lymphoma samples, miR-124-1 was preferentially
hypermethylated in B- or NK/T-cell lymphomas and associated with reduced miR-124 expression. In conclusion, miR-124-1
was hypermethylated in a tumour-specific manner, with a heterochromatic histone configuration. Hypomethylation led to
partial restoration of euchromatic histone code and miR re-expression. Infrequent miR-124-1 methylation detected in
diagnostic and relapse MM samples showed an unimportant role in MM pathogenesis, despite frequent methylation found
in cell lines. Amongst haematological cancers, miR-124-1 was more frequently hypermethylated in NHL, and hence warrants
further study.
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Introduction
DNA methylation involves the addition of a methyl group to the
number 5 carbon of the cytosine ring in the CpG dinucleotide, by
catalyzing the cytosine into methylcytosine through DNA methyl-
transferase [1,2]. Cancer cells are characterized by global DNA
hypomethylation but gene-specific hypermethylation of promoter-
associated CpG islands of tumour suppressor genes (TSGs),
resulting in transcriptional repression, and hence serve as an
alternative mechanism of gene inactivation. Based on a pathway-
specific approach, multiple TSGs across pathways including cell
cycle regulation, JAK/STAT signalling, WNT signalling, and DAP
kinase-associated intrinsic tumour suppression have been shown to
be inactivated by gene hypermethylation in leukaemia, lymphoma
and multiple myeloma [3,4,5,6,7,8,9,10,11].
MicroRNA (miR) is a single-stranded, non-coding RNA
molecule of 22–25 nucleotides, which leads to downregulation of
target protein expression [12]. miRs are involved in carcinogen-
esis. miRs can be either oncogenic (oncomir) when TSGs are
targeted, or tumour suppressive (tumour suppressor miRs) when
oncogenes are targeted [12,13]. Little is known about the role of
hypermethylation of tumour suppressor miRs in haemic cancers.
Recently, miR-124-1 has been shown to be hypermethylated in
multiple cancers [14,15]. By luciferase assay, miR-124-1 has been
shown to downregulate CDK6 translation by binding on the 39
untranslated region (39 UTR) of the CDK6 mRNA, and also
reduce the retinoblastoma protein phosphorylation, thereby
demonstrating the tumour suppressor role of miR-124-1 [14].
In this study, we aimed to study the role of miR-124-1
methylation in a wide range of haematological malignancies
including acute myeloid leukaemia (AML), chronic myeloid
leukaemia (CML), acute lymphoblastic leukaemia (ALL), chronic
lymphocytic leukaemia (CLL), multiple myeloma (MM) and non-
Hodgkin’s lymphoma (NHL).
Materials and Methods
Patient samples
Diagnostic bone marrow or tissue samples were obtained in 20
ALL, 20 AML, 11 CML in chronic phase, 50 CLL, 55 MM and
PLoS ONE | www.plosone.org 1 April 2011 | Volume 6 | Issue 4 | e19027
74 NHL patients. Diagnosis of leukaemia and lymphoma were
made according to the French-American-British Classification and
WHO Classification of Tumours respectively [16,17,18,19]. Of
the 20 ALL patients, there were eleven male and nine female
patients with a median age of 35 years (range: 13–62). There were
six common ALL, one early B precursor, ten precursor B ALL and
three pre-T ALL. Of the AML patients, there were nine male and
eleven female with a median age of 41.5 years (range: 20–72). The
AML cases comprised three M1, fourteen M2, two M4 and one
M5 subtype. Of the 50 CLL patients, there were twenty three
(46%) patients with limited stage (,stage II) and twenty seven
(54%) with advanced stage ($stage II) disease with a median age
of 65.5 years (range: 37–91) [3]. Forty (80%) were male. The
median presenting lymphocyte count was 176109/L (range: 10–
2366109/L). Of the 55 MM patients, the median age was 57 (25–
87) years. The diagnosis of MM was based on standard criteria
[20]. Apart from five patients with insufficient clinical data, there
were seven (14%) Durie-Salmon stage I, thirteen (26%) stage II,
and thirty (60%) stage III patients. In order to study if miR-124-1
methylation might be acquired at the time of relapse or after
repeated chemotherapy, a total of 53 serial samples from 12 MM
patients including those at stable disease, refractory relapse,
relapse, primary refractory disease or refractory disease progres-
sion were included. Of the 74 patients with NHL, there were 17
patients with peripheral T cell lymphoma (two anaplastic large cell
[ALCL], four angio-immunoblastic T-cell [AITL], eleven periph-
eral T-cell, not otherwise specified [PTCL, NOS]), 10 with natural
killer (NK)/T-cell lymphoma, 47 patients with B-cell lymhoma
(twenty-one follicular: grade 1 to 2, eight nodal marginal zone,
three mantle cell lymphoma and fifthteen diffuse large B-cell
lymphoma). The study has been approved by Institutional Review
Board of Queen Mary Hospital with informed consent.
Cell lines and culture
Lymphoma (SU-DHL-1, SUP-M2, SUP-T1, and KARPAS-
299) and MM (KMS-12-PE, MOLP-8, OPM-2, and U-266) cell
lines were purchased from Deutsche Sammlung von Mikroorga-
nismen und Zellkulturen GmbH (DMSZ) (Braunschweig, Ger-
many). LP-1 and RPMI-8226 were kind gifts from Dr Orlowski
(Department of Hematology/Oncology, MD Anderson Cancer
Center, USA). WL-2 was kindly provided by Dr Andrew
Zannettino (Myeloma and Mesenchymal Research Laboratory,
Division of Haematology, Institute of Medical and Veterinary
Science, Adelaide, Australia). NCI-H929 was purchased from
American Type Culture Collection (ATCC). Cell cultures were
maintained in RPMI media 1640 (IMDM for LP-1) (Invitrogen,
Carlsbad, CA, USA), supplemented with 10% fetal bovine
serum (Invitrogen, Carlsbad, CA, USA), 50 U/ml penicillin, and
50 mg/ml streptomycin (Invitrogen, Carlsbad, CA, USA) in a
humidified atmosphere of 5% CO2 at 37uC.
Methylation-specific polymerase chain reaction (MSP)
DNA was extracted from bone marrow samples of ALL, AML,
CML, CLL, and MM at diagnosis, diagnostic tissues (either lymph
node or nasal biopsy in nasal NK-cell lymphoma) in patients with
NHL, and lymphoma and MM cell lines by standard method.
MSP for aberrant gene promoter methylation was performed as
previously described [8]. Treatment of DNA with bisulfite for
conversion of unmethylated cytosine to uracil (but unaffecting
methylated cytosine) was performed with a commercially available
kit (EpiTect Bisulfite Kit, QIAGEN, Hilden, Germany). Primers
used for the methylated MSP (M-MSP) and unmethylated MSP
(U-MSP) were published previously [14]. DNA from normal bone
marrow donors (N= 5) was used as negative control, while
enzymatically methylated control DNA (CpGenome Universal
Methylated DNA, Chemicon, Temecula, CA, USA) was used as
positive control in all the experiments.
Bisulfite genomic sequencing (BGS)
Bisulfite-treated DNA was used as template. Promoter region of
miR-124-1 was amplified and cloned using TOPO TA Cloning Kit
(Invitrogen, Carlsbad, CA, USA) according to the manufacturer’s
instructions. Primers used were published previously [14].
5-Aza-29-deoxycytidine (5-AzadC) treatment
For treatment with 5-AzadC (Sigma-Aldrich, St. Louis, MO,
USA), cells were seeded in six-well plates at a density of 16106
cells/ml, and cultured with 1 mM of 5-AzadC for 3 days. Cells on
day 0 and day 3 of 5-AzadC treatment were harvested.
RNA isolation and stem-loop reverse
transcription-polymerase chain reaction (RT-PCR)
Total RNA was isolated using mirVanaTM miR Isolation Kit
(Ambion, Austin, TX, USA), according to the manufacturer’s
instructions. RT was performed using TaqmanH MicroRNA RT
Kit and TaqmanH MicroRNA Assay Kit (Applied Biosystems,
Foster City, CA, USA), according to the manufacturer’s
instructions. Total RNA was reverse transcribed in 1 mM dNTPs,
50 U MultiScribeTM Reverse Transcriptase, 16RT Buffer, 3.8 U
RNase Inhibitor, and 16 stem-loop RT primer at following
thermal cycling condition: 16uC for 30 minutes, 42uC for
30 minutes, and 85uC for 5 minutes. Quantitative real-time
PCR of miR-124 was performed using 1.33 ml of 1:15 diluted
RT product in 16TaqmanH Universal PCR Master Mix, and 16
TaqmanH Assay at 95uC for 10 minutes, followed by 40 cycles of
95uC for 15 seconds and 60uC for 1 minute. RNU48 was used as
reference for data analysis using the 22DDCt method [21].
Chromatin immunoprecipitation (ChIP)
ChIP assays were conducted according to manufacturer’s
instructions (Upstate, Cat# 17-610). Cells of 26106 were fixed
in 1% formaldehyde for each ChIP. Fixed cells were washed by
cold PBS, resuspended in lysis buffer, and sheared into fragments
ranging between 200 and 800 bp in size on ice using 431A cup
horn (Misonix, Farmingdale, NY, USA). ‘Input’ of 1% was
reserved as control, immunoprecipitation was performed by 4uC
overnight incubation with anti-H3K4me3 (Upstate, 04-745), anti-
H3K9me3 (Upstate, 17-625; Abcam, 8898), anti-H3K9ac (Up-
state, 17-658), anti-H3K27me3 (Upstate, 17-622) and normal
rabbit IgG respectively. Immunoprecipitated complex was col-
lected by magnetic protein A beads. The complex was washed,
treated with proteinase K, and reverse cross-linked by heat.
Primers used for ChIP-PCR of miR-124-1 were forward: 59- CAA
AGA GCC TTT GGA AGA CG -39 and reverse: 59- GGA AGA
GGG GTG GGT AGA AG -39. ChIP-PCR was also controlled by
GAPDH promoter and Alu repeats [22,23].
Western blot for CDK6
Cells were harvested and lysed in RIPA buffer (50 mM Tris-
HCl, pH 7.4, 150 mM NaCl, 0.2% SDS, 1% Triton X-100,
2 mM EDTA) supplemented with protease inhibitors including
4 mg/ml aprotinin, 2 mg/ml leupeptin, 1 mg/ml pepstatin A,
20 mg/ml PMSF, and 1 mM Na3VO4. Cell debris was removed
by centrifugation at 10,0006g for 5 minutes at 4uC. Protein lysate
was denatured in an equal volume of loading buffer (100 mM
Tris-HCl, pH 6.8, 200 mM DTT, 4% SDS, 0.2% bromophenol
blue, 20% glycerol), heated at 95uC for 5 minutes, and separated
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Figure 1. Methylation of miR-124-1. (A) Schematic diagram showing the distribution of CpG dinucleotides (solid vertical lines) over the precursor
(solid black box) and mature miR-124-1. Sequence analysis of the M-MSP product from bisulfite-treated positive control DNA showed that the
cytosine [C] residues of CpG dinucleotides were methylated and remained unchanged, whereas all the other C residues were unmethylated and were
converted to thymidine [T], indicating complete bisulfite conversion and specificity of MSP. Grey bars indicated the amplification regions of the MSP,
ChIP, and BGS primers. (B) U-MSP showed that the methylated positive control [P] was totally methylated, and all five normal controls (N1–N5) were
unmethylated. In the M-MSP, the methylated control was positive (methylated) but all normal controls were negative (unmethylated). For the cell
lines, SUP-T1, SUP-M2 (ALK+), SU-DHL-1 (ALK+), KARPAS-299 (ALK+), KMS-12-PE, LP-1, OPM-2, and WL-2 were completely methylated of miR-124-1. (C)
Bisulfite genomic sequencing for the bisulfite-treated promoter region of miR-124-1 of normal controls (N1–N5), lymphoma and myeloma cell lines of
different methylation statuses (MM, UM, or UU), and the methylated positive control were depicted. Unmethylated (empty circle) and methylated
(filled circle) CpG dinucleotides were shown by eight independent clones for each sample.
doi:10.1371/journal.pone.0019027.g001
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on 10% SDS-PAGE. Separated samples were then transferred to a
0.2 mm nitrocellulose membrane (Bio-Rad, Hercules, CA). The
membrane was blocked at room temperature for 1 hour in 5%
skim milk diluted in PBS-Tween 20 (0.5% v/v). The membrane
was then incubated with CDK6 primary antibody (1:1000) at 4uC
overnight with shaking. After washing 3 times of 15 minutes each
in PBS-Tween 20 (0.5% v/v), the membrane was incubated with
anti-mouse horseradish peroxidase conjugate secondary antibody
(1:1000) at room temperature for 1 hour. After washing 3 times of
15 minutes each in PBS-Tween 20 (0.5% v/v), signals were
detected by ECL Western blotting detection reagents (Amersham
Biosciences, Buckinghamshire, UK) and exposed to X-ray film.
Statistical analysis
The frequency of miR-124-1 methylation in different types of
haematological cancers was computed by Chi-Square or Fisher
Exact test. In CLL, correlation between miR-124-1 methylation
status with continuous (mean age, mean diagnostic haemoglobin,
lymphocyte and platelet counts) and categorical variables (gender
and Rai staging) were studied by Student t-test and Chi-square test
(or Fisher Exact test) respectively. Overall survival (OS) is
measured from the date of diagnosis to the date of last follow-up
or death. OS of patients with limited Rai stage (stages 0, I and II)
were compared to those with advanced stage (stage III and IV).
Survival is plotted by the Kaplan-Meier method and compared by
the log-rank test. All p-values were two-sided. In NHL, correlation
between miR-124-1 methylation with continuous (mean age) and
categorical variables (gender, histological subtypes, lineage [B, T
or NK/T] and nodal/extranodal presentation) were studied in 49
patients with complete clinical data by Student’s t-test and Chi-
square test (or Fisher Exact test) respectively. Moreover, in 25
primary B-cell NHL samples in which both DNA and RNA were
available, the mean expression of miR-124 in methylated and
unmethylated lymphoma were compared by the Student’s t-test.
Results
MSP
Controls. Direct sequencing of the M-MSP products from
the methylated positive control showed the expected nucleotide
changes after bisulfite treatment, therefore confirming complete
bisulfite conversion and specificity of MSP (Figure 1A). None of
the five normal control marrows showed aberrant methylation of
miR-124-1 (Figure 1B). The positive and negative controls showed
the expected MSP results (normal DNA: U-MSP positive/M-MSP
negative; methylated DNA: U-MSP negative/M-MSP positive).
Lymphoma cell lines. The profile of methylation of miR-
124-1 of lymphoma cell lines was shown in Figure 1B. SUP-T1,
SUP-M2 (ALK+), SU-DHL-1(ALK+) and KARPAS-299 (ALK+)
were homozygously methylated for miR-124-1.
Myeloma cell lines. The profile of methylation of miR-124-1
of myeloma cell lines was shown in Figure 1B. Apart from MOLP-
8 and RPMI-8226, which were completely unmethylated (UU) of
miR-124-1, KMS-12-PE, LP-1, OPM-2, and WL-2 were
homozygously methylated (MM) for miR-124-1, whereas NCI-
H929 and U-266 were hemizygously methylated (MU) for miR-
124-1.
Bisulfite genomic sequencing confirmed miR-124-1 hypomethy-
lation in five normal controls, hypermethylation in the methylated
positive control, and the corresponding methylation statuses (MM,
MU, and UU) as detected by MSP (Figure 1C).
Primary samples at diagnosis. miR-124-1 hypermethylation
was not detected in any of the CML. On the other hand, miR-124-1
methylation was found in one (2%) MM samples at diagnosis, one
(2%) MM samples at relapse/progression, 1 (5%) ALL, 3 (15%)
AML, 7 (14%) CLL and 43 (58.1%) NHL samples (p,0.001)
(Figure 2A). Amongst the lymphoid malignancies, there was
significantly more frequent miR-124-1 methylation in NHL than
MM, CLL or ALL (p,0.001). In CLL, there was no correlation
between miR-124-1methylation and age (p=0.79), gender (p=0.99),
diagnostic lymphocyte count (p=0.89); Hb (p=0.98), platelet count
(p=0.42), advanced Rai stage ($stage 2) (p= 0.69) and death
(p=0.41). The projected OS in CLL patients with and without miR-
124-1 methylation were 86% and 62% (p=0.36). Amongst
lymphoma samples, miR-124-1 was methylated in seven NK/T
(70.0%), thirty-one B-cell NHL (66.0%), and five T-cell NHL (29.4%)
(p=0.023). However, miR-124-1 methylation did not correlate with
age (p=0.457), gender (p=0.99) or Ann Arbor stage (p=0.105) of
the lymphoma patients.
In order to determine the role of miR-124-1 methylation on the
expression of miR-124 in primary samples, we analyzed the
methylation status and expression level in 25 primary B-cell NHL
samples in which both DNA and RNA were available. By MSP
and stem-loop qRT-PCR, 22 samples displayed methylated MSP
signals and three were completely unmethylated (Figure 2B).
Moreover, methylation of miR-124-1 was associated with a lower
level of miR-124 expression, and hence a higher DCt (Ct miR-124 -
Ct RNU48) (p = 0.01) (Figure 2C).
5-AzadC treatment of lymphoma and myeloma cells
SU-DHL-1, KARPAS-299, KMS-12-PE, and WL-2 cells were
completely methylated for miR-124-1. Upon 5-AzadC demethyl-
ation treatment, miR-124-1 U-MSP signal emerged on day 3, with
re-expression of mature miR-124 as shown by Taqman stem-loop
qRT-PCR (Figure 3A). 5-AzadC treatment led to augmentation of
euchromatic histone code with abundance of trimethyl H3K4 at
miR-124-1 promoter region (Figure 3B). GAPDH promoter and Alu
repeat element, with the inherent hypo- and hypermethylated
DNA, were used as biological controls for euchromatin and
heterochromatin configurations (Figure 3B). Finally, demethyla-
tion of miR-124-1 by 5-AzadC with miR-124 re-expression led to
downregulation of CDK6 (Figure 3C).
Discussion
There are several observations.
Firstly, in this study, we showed that miR-124-1 is not methylated
in normal blood cells but is hypermethylated in lymphoma and
myeloma cell lines, which can be re-expressed upon hypomethylat-
ing treatment. In cancer, miRs may be hypermethylated by two
patterns. First, tumour suppresssor miRs are expected to be
hypomethylated in normal cells but hypermethylated in cancer
cells [24]. On the other hand, some miRs may be hypermethylated
in both normal and tumour cells, and therefore, hypermethylation
of these miRs is tissue-specific but not tumour-specific. For example,
miR-127 and miR-373 are hypermethylated in both the normal and
cancer cells [24,25]. Therefore, our data and those from Lujambio
et al. showed that miR-124-1 is differentially methylated in cancer
Figure 2. Promoter methylation of miR-124-1 and expression of miR-124 in primary samples. (A) Methylation of miR-124-1 in primary
samples. (B) M-/U-MSP analysis of miR-124-1 promoter methylation status and (C) Stem-loop qRT-PCR analysis of the maturemiR-124 expression in 25
primary NHL samples with matched DNA and RNA. DCt, Ct miR-124 -Ct RNU48.
doi:10.1371/journal.pone.0019027.g002
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cells but not normal cells, consistent with its tumour suppressor role
[14]. In addition to miR silencing associated with miR-124-1
methylation, miR expression could be restored by miR-124-1
demethylation, which was associated with restoration of the
euchromatin code trimethyl H3K4. Moreover, miR-124-1 re-
expression after hypomethylating treatment was associated with
downregulation of CDK6 expression, consistent with data that
CDK6 is a target of translation repression by miR-124-1 [14].
Furthermore, to ensure ChIP specificity, we showed two trimethyl
H3K9 antibodies of different preparations generated comparable
results, which further controlled the ChIP technically together with
input and IgG controls; in addition to GAPDH and Alu repeat
element, with the inherent hypo- and hypermethylated DNA, which
served as biological controls for euchromatin and heterochromatin
configurations.
Secondly, as miR-124-1 is localized to chromosome 8p, where
loss of heterozygosity (LOH) is frequently found in various solid
cancers [26,27,28,29], and certain subtypes of NHL including
mantle cell [30], and small B cell lymphoma [31]. Therefore, miR-
124-1 hypermethylation may collaborate with LOH to result in
biallelic miR-124-1 inactivation in NHL, thereby fulfilling the
Knudson’s hypothesis [32]. This was supported by the finding that
miR-124-1 was preferentially methylated in lymphoma, in
particular, in B- and NK/T-cell lymphomas, which was associated
with a lower expression of miR-124. Therefore methylation of miR-
124-1 might be important in lymphomagenesis.
Fourthly, miR-124-1 was preferentially hypermethylated in NK/
T-cell lymphoma, which is an Epstein-Barr virus–associated,
aggressive extranodal lymphoma more frequently encountered in
Asia, and Central and South America [33]. Various tumour
suppressor genes have been shown to be frequently hypermethy-
lated in NK/T-cell lymphoma including p73, CDKN2A, CDKN2B,
hMLH1 and RARb [34], but hypermethylation of miR-124-1 is one
of the first reports of methylation of miR in NK/T-cell lymphoma.
On the other hand, in contrast to frequent (del)8p in B-cell
lymphoma, del(8p) is infrequent in NK/T-cell lymphoma [35], and
hence, in NK/T-cell lymphomas, miR-124-1 might be inactivated
by biallelic hypermethylation instead of deletion together with gene
hypermethylation. Apart from NHL, miR-124-1 methylation is
infrequent in other haematological malignancies in contrast to solid
cancer such as colon and lung cancers, in which miR-124
methylation was detected in 48%–75% of primary samples [14].
On the other hand, in contrast to a previous report of frequent
hypermethylation of miR-124 in ALL [36], only 5% of ALL patients
carried hypermethylation of miR-124-1 in this series. Possible
reasons included the small sample size here and the inclusion of
merely adult but not paediatric patients in our study.
Finally, despite frequent hypermethylation of miR-124-1 in
myeloma cell lines, miR-124-1 methylation was found infrequent
in diagnostic marrow samples, and hence we postulated that miR-
124-1 methylation may be acquired during disease progression or
after repeated chemotherapy. In particular, we included samples
after repeated chemotherapy regimens after clinical relapse.
However, no significant methylation of miR-124-1 was demonstrat-
ed in relapsed myeloma marrow samples either, even after repeated
intensive chemotherapy regimens. Therefore, miR-124a methyla-
tion is unimportant in the pathogenesis or progression of MM.
In summary, miR-124-1 hypermethylation is tumour-specific,
associated with gene silencing, which can be reversed by
hypomethylating treatment. Re-expression of miR-124 by 5-
AzadC treatment was associated with emergence of a partial
euchromatin histone code and consequent downregulation of
CDK6. Amongst haematological malignancies, miR-124-1 is
preferentially hypermethylated in NHL (in particular NK/T-cell
lymphoma), in which methylation of miR-124-1 was associated
with a lower expression of miR-124, and hence warrant further
study in lymphoma. Finally, in MM, despite frequent miR-124-1
methylation in myeloma cell lines, miR-124-1 methylation was
infrequent in primary samples including relapse samples, and
hence unimportant in myeloma pathogenesis.
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